A 12-week four-arm randomised trial in 36 male recreational athletes found that combined diet plus exercise improved body composition and glycaemic markers, with small effect sizes. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A secondary analysis of the VA NEPHRON-D cohort found that higher baseline urinary EGF and uromodulin were independently associated with a lower risk of diabetic kidney disease progression. PICO summary and expert commentary.
Once-weekly fixed-dose insulin efsitora was noninferior to once-daily glargine for HbA1c reduction over 52 weeks in insulin-naive type 2 diabetes, with less hypoglycaemia. PICO summary and expert commentary.
A 16-week randomized trial found combined training lowered GLP-1 and amylin and raised DPP-4 in adults with type 2 diabetes and overweight, without a demonstrated glycaemic benefit. PICO summary and expert commentary.
A randomized trial testing whether a patient previsit activation handout, added to physician academic detailing, increases diabetes medication deprescribing in adults 75 and older. PICO summary and expert commentary.
A 26-week double-blind randomised trial testing once-weekly semaglutide added to automated insulin delivery in 72 adults with type 1 diabetes and obesity. PICO summary and expert commentary.
An exploratory open-label RCT found imeglimin and metformin lowered HbA1c similarly, but only imeglimin raised insulin and GIP secretion. PICO summary and expert commentary.
A secondary analysis of a metformin-versus-insulin gestational diabetes trial found cord serum lipids associated with offspring beta-cell function at age nine. PICO summary and expert commentary.
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.
Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.